# Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine

> **NCT05707949** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **AbbVie** · enrollment: 650 (estimated)

## Conditions studied

- Migraine Prophylaxis

## Interventions

- **DRUG:** Atogepant

## Key facts

- **NCT ID:** NCT05707949
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-06-05
- **Primary completion:** 2032-04
- **Final completion:** 2032-04
- **Target enrollment:** 650 (ESTIMATED)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05707949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05707949, "Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05707949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*